Evidence map›Paper›PMID 40490087›Full record

ArticleBrain research2025

Tauroursodeoxycholic acid reduces brain lesion volume and cortical edema in a rat model of Traumatic brain injury.

Eder Cáceres, Pascal Salazar, Michel T Torbey, Colin M Wilson, Denis E Bragin, Reed G Selwyn, Afshin A Divani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Eder CáceresUnisabana Center for Translational Science, School of Medicine, Universidad de La Sabana, Chía, Colombia; Bioscience PhD. School of Engineering, Universidad de La Sabana, Chía, Colombia; Department of Critical Care, Clínica Universidad de La Sabana, Chía, Colombia.
Pascal SalazarCanon Medical Informatics, Inc., Minnetonka, MN, USA.
Michel T TorbeyDepartment of Neurology, University of Oklahoma, Oklahoma City, OH, USA.
Colin M WilsonDepartment of Radiology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Denis E BraginLovelace Biomedical Research Institute, 2425 Ridgecrest Dr. SE, Albuquerque, NM, USA; Department of Neurology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Reed G SelwynDepartment of Radiology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Afshin A DivaniDepartment of Neurology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA. Electronic address: adivani@gmail.com.

Funding

University of New Mexico (UNM) Center for Brain Recovery and RepairP20GM109089 · NIGMS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI SHUTTLEWORTH, CLAUDE W · 2015 to 2024
$22.7M
Brain Injury Treatment by Modulation of Hemodynamics With Blood Soluble Drag Reducing MoleculesR01NS112808 · NINDS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI BRAGIN, DENIS E. · 2019 to 2023
$2.1M
Stroke Treatment by Modulation of Hemodynamics with Drag Reducing MoleculesR21NS091600 · NINDS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI BRAGIN, DENIS E. · 2015 to 2016
$423k
Noninvasive Vagus Nerve Stimulation for Treatment of Brain Injury (nVNS-TBI) in RatsR21NS130423 · NINDS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI DIVANI, AFSHIN ANDRE · 2022 to 2022
$419k
NIGMS NIH HHS P20 GM109089NINDS NIH HHS R01 NS112808NINDS NIH HHS R21 NS091600NINDS NIH HHS R21 NS130423
6 · The paper itself

Abstract

backgroundTraumatic brain injury (TBI) continues to be a major cause of death and disability worldwide. Effective treatment options are limited, and randomized clinical data has been futile.

objectiveIn this study, we assessed the efficacy of tauroursodeoxycholic acid (TUDCA) in treating TBI using a controlled cortical impact injury model in male Wistar rats.

methodsAnimals were randomized into two experimental groups: 1) TBI with sham treatment (Control, n = 12) and 2) TBI treated with intravenous infusion of 300 mg/kg TUDCA (TUDCA-treated group, n = 10) 30 min post-injury. Anxiety levels and magnetic resonance imaging studies were performed on days 1 and 7 post-injury. Animals were euthanized on day 7 for histopathological assessments.

resultsOn days 1 and 7, we observed a smaller brain lesion volume in the TUDCA-treated group compared with the Control group and greater cytotoxic edema on day 1 in the Control group. Elevated plus maze revealed a lower anxiety index for the TUDCA-treated group on day 7.

conclusionOur study showed that TBI rats treated with TUDCA at a hyperacute stage had a statistically significant reduction in lesion volume and improved levels of anxiety. However, a dose-response relationship and ideal therapeutic window still need to be determined. Future studies should consider a multiday therapy paradigm to identify the optimum intervention frequency in a mixed-gender.

Indexed as

Brain EdemaBrain Injuries, TraumaticNeuroprotective AgentsTaurochenodeoxycholic AcidAnimalsAnxietyBrainDisease Models, AnimalMagnetic Resonance ImagingMaleRatsRats, WistarNeuroprotective AgentsTaurochenodeoxycholic AcidursodoxicoltaurineBrain lesion volumeCortical edemaMagnetic resonance imagingNeurobehavioral outcomesTauroursodeoxycholic acidTraumatic brain injury

Identifiers

PMID40490087
PMCPMC12488038

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.